Evotec SE
https://www.evotec.com/en
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Evotec SE
Deal Watch: Organon Obtains Rights To Perjeta, Prolia/Xgeva Biosimilars From Shanghai Henlius
Biosimilar licensing agreement also includes option on Yervoy-based product. Oxford BioTherapeutics, ImmunoGen pair their technologies for development of novel cancer ADCs.
Juicy Apples Come From Healthy Trees: Advice For Platform Developers
Speaking at BIO-Europe Spring, three leaders of platform life sciences companies offer advice on their scalable and lower risk business models that support innovation within partner biopharma companies.
Almirall Throws Down Gauntlet To Dupixent With New Lebrikizumab Data
The Spanish group has revealed that eight out of ten atopic dermatitis patients treated with lebrikizumab maintained skin clearance after a year, which compares favorably with Sanofi and Regeneron's blockbuster Dupixent.
Deal Watch: Innoviva To Buy The Rest Of Entasis For Enterprise Value Of $113m
Already owner of about 60% of the troubled antibiotic firm, Innoviva agrees to pay $2.20 per share for all outstanding stock in Entasis. Roche, KaliVir partner on oncolytic virus therapies.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
-
Drug Discovery Tools
- Bioinformatics
- Other Names / Subsidiaries
-
- Aptuit
- Bionamics GmbH
- Cyprotex PLC
- DeveloGen AG
- Euprotec Ltd
- Evotec AG
- Evotec BioSystems GmbH
- Evotec Neurosciences GmbH
- Evotec BioSystems AG
- Just Biotherapeutics, Inc.
- Kinaxo Biotechnologies
- Compound Focus
- Renovis
- Just – Evotec Biologics, Inc.